Logo Coronavir.org

Coronavir.org

Site de veille et d'information sur le nouveau coronavirus SARS-COV-2 et la maladie associée COVID-19

Actualités et recherches en cours

After one year of stop-and-go COVID-19 mitigation, some European countries still experience sustained viral circulation due to the B.1.1.7 variant. As the prospect of phasing out this stage through vaccination draws closer, it is critical to balance the efficacy of long-lasting interventions and their impact on the quality of life. Focusing on the current situation in France, we show that moderate interventions require a much longer time to achi...

IntroductionTraditional surveillance methods have been enhanced by the emergence of online participatory syndromic surveillance systems that collect health-related digital data. These systems have many applications including tracking weekly prevalence of Influenza-Like Illness (ILI), predicting probable infection of Coronavirus 2019 (COVID-19), and determining risk factors of ILI and COVID-19. However, not every volunteer consistently completes ...

BackgroundIn March 2021, the Biden administration allocated $10 billion for COVID-19 diagnostic and screening tests in schools. ObjectiveWe address to what extent screening tests reduce the risks of full-time in-person learning and how costs of testing compare to short-term financial costs of reduced in-person educational time, at different levels of community incidence. DesignWe used an agent-based network model to simulate transmission in el...

The emergence of SARS-CoV-2, leading to COVID-19, necessitated the development of new molecular and serological tests. Here, we describe a multiplexed serological assay developed as the global pandemic moved into New York State in the spring of 2020. The original microsphere immunoassay used a target antigen from the SARS-CoV-1 virus responsible for the 2003 SARS outbreak, but evolved to incorporate multiple SARS-CoV-2 protein antigens (nucleoca...

BackgroundThe success of social distancing implementations of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) depends heavily on population compliance. Mathematical modelling has been used extensively to assess the rate of viral transmission from behavioural responses. Previous epidemics of SARS-Cov-2 have been characterised by superspreaders, a small number of individuals who transmit a disease to a large group of individuals, who ...

Background Vaccination constitutes the best long-term solution against Coronavirus Disease 2019 (COVID-19). Real-world immunogenicity data are sparse, particularly for ChAdOx1 and in populations with chronic conditions; and given the extended dosing interval in the UK, it is also important to understand antibody responses in SARS-CoV-2-naive individuals following a single dose. Methods Adults aged 18+ years from households enrolled in Virus Watc...

We consider models for the importation of a new variant COVID-19 strain in a location already seeing propagation of a resident variant. By distinguishing contaminations generated by imported cases from those originating in the community, we are able to evaluate the contribution of importations to the dynamics of the disease in a community. We find that after an initial seeding, the role of importations becomes marginal compared to that of commun...

BackgroundVaccine hesitancy in the U.S. may limit the potential to alleviate the public health threat caused by the COVID-19 pandemic. MethodsWe estimated trends in and correlates of vaccine hesitancy, and its association with subsequent vaccine uptake among 5,085 United States adults from the CHASING COVID Cohort study, a national longitudinal study. Trends in willingness to vaccinate were examined longitudinally in three rounds of interviews ...

BackgroundCovid-19 vaccines are urgently needed, especially against emerging variants. NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 rS) nanoparticle vaccine containing trimeric full-length SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant. MethodsA phase 3, randomized, observer-blinded, placebo-controlled trial was conducted in adults 18-84 years old who received two intramuscular 5-{micro}g doses, ...

mRNA-based vaccines effectively induce protective neutralizing antibody responses against SARS-CoV-2, the etiological agent of COVID-19. The specific compositional patterns of these responses remain largely unknown. We found that SARS-CoV-2-naive individuals receiving the first dose of an mRNA vaccine developed a SARS-CoV-2-specific antibody response with a subclass profile comparable to that induced by the natural infection, except IgA2, which ...

Important : Le contenu diffusé sur Coronavir.org ne doit jamais remplacer les conseils d'un médecin ou des autorités de santé locales.